Introduction: The present study evaluated the prognostic significance of panimmune-inflammation value (PIV) and PILE (a composite score of PIV, lactate dehydrogenase [LDH], and Eastern Cooperative Oncology Group Performance Status [ECOG PS]) in patients with non-metastatic luminal A breast cancer. Methods: Non-metastatic stage (I–III) luminal A breast cancer patients who were admitted to Cumhuriyet University Oncology Center were retrospectively examined. The PIV score was calculated using the neutrophil, platelet, monocyte, and lymphocyte counts at the time of diagnosis. The PIV, LDH, and ECOG PS parameters were used for the PILE score. Results: A total of 293 patients were included. The median PIV was 254.89; 239 (82%) patients had low PILE score; and 54 (18%) patients had high PILE score. Patients with low PIV and low PILE scores had significantly better OS and disease-free survival (DFS) (PIV; p = 0.033 for OS and p = 0.024 for DFS and PILE; p = 0.001 for OS and p = 0.005 for DFS). The PIV and PILE scores were found to be significant prognostic factors associated with OS and DFS. The PIV score was found to be an independent prognostic factor for OS and DFS (OS: score 0 vs. 1; HR: 1.89, 95% CI: 1.06–3.35; p = 0.029; and DFS: score 0 vs. 1; HR: 1.75, 95% CI: 1.01–3.01; p = 0.044). The PILE score was not an independent prognostic factor associated with OS or DFS. Conclusion: Survival was better in those with lower PIV and PILE scores. The PIV score was an independent prognostic factor for survival in these patients.

1.
Perou
CM
,
Sørlie
T
,
Eisen
MB
,
van de Rijn
M
,
Jeffrey
SS
,
Rees
CA
, et al
.
Molecular portraits of human breast tumours
.
Nature
.
2000
;
406
(
6797
):
747
52
.
2.
Yersal
O
,
Barutca
S
.
Biological subtypes of breast cancer: prognostic and therapeutic implications
.
World J Clin Oncol
.
2014
;
5
(
3
):
412
24
.
3.
Goldhirsch
A
,
Winer
EP
,
Coates
AS
,
Gelber
RD
,
Piccart-Gebhart
M
,
Thürlimann
B
, et al
.
Personalizing the treatment of women with early breast cancer: highlights of the St gallen international Expert Consensus on the primary therapy of early breast cancer 2013
.
Ann Oncol
.
2013
;
24
(
9
):
2206
23
.
4.
Ligorio
F
,
Fucà
G
,
Zattarin
E
,
Lobefaro
R
,
Zambelli
L
,
Leporati
R
, et al
.
The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (HER2)-Positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab
.
Cancers
.
2021
;
13
(
8
):
1964
.
5.
Corti
F
,
Lonardi
S
,
Intini
R
,
Salati
M
,
Fenocchio
E
,
Belli
C
, et al
.
The pan-immune-inflammation value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors
.
Eur J Cancer
.
2021
;
150
:
155
67
.
6.
Fucà
G
,
Guarini
V
,
Antoniotti
C
,
Morano
F
,
Moretto
R
,
Corallo
S
, et al
.
The pan-immune-inflammation value is a New prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the valentino and TRIBE first-line trials
.
Br J Cancer
.
2020
;
123
(
3
):
403
9
.
7.
Guven
DC
,
Yildirim
HC
,
Bilgin
E
,
Aktepe
OH
,
Taban
H
,
Sahin
TK
, et al
.
PILE: a candidate prognostic score in cancer patients treated with immunotherapy
.
Clin Transl Oncol
.
2021
;
23
(
8
):
1630
6
.
8.
Karadağ
I
,
Karakaya
S
,
Yılmaz
ME
,
Çakmak Öksüzoğlu
ÖB
.
The potential prognostic novel markers PIV and PILE score to predict survival outcomes at hepatocellular cancer
.
Eur Rev Med Pharmacol Sci
.
2022
;
26
(
20
):
7679
86
.
9.
Zeng
R
,
Liu
F
,
Fang
C
,
Yang
J
,
Luo
L
,
Yue
P
, et al
.
PIV and PILE score at baseline predict clinical outcome of anti-PD-1/PD-L1 inhibitor combined with chemotherapy in extensive-stage small cell lung cancer patients
.
Front Immunol
.
2021
;
12
:
724443
.
10.
Wolff
AC
,
Hammond
ME
,
Schwartz
JN
,
Hagerty
KL
,
Allred
DC
,
Cote
RJ
, et al
.
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
.
J Clin Oncol
.
2007
;
25
(
1
):
118
45
.
11.
Hammond
ME
,
Hayes
DF
,
Dowsett
M
,
Allred
DC
,
Hagerty
KL
,
Badve
S
, et al
.
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer
.
J Clin Oncol
.
2010
;
28
(
16
):
2784
95
.
12.
Hong
X
,
Cui
B
,
Wang
M
,
Yang
Z
,
Wang
L
,
Xu
Q
.
Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer
.
Tohoku J Exp Med
.
2015
;
236
(
4
):
297
304
.
13.
Hu
B
,
Yang
XR
,
Xu
Y
,
Sun
YF
,
Sun
C
,
Guo
W
, et al
.
Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma
.
Clin Cancer Res
.
2014
;
20
(
23
):
6212
22
.
14.
Li
QX
,
Shi
DJ
,
Zhang
LX
,
Wang
DM
,
Zhao
J
,
Wang
T
, et al
.
Association of body mass and systemic immune-inflammation indices with endocrine therapy resistance in luminal breast cancers
.
J Int Med Res
.
2019
;
47
(
5
):
1936
47
.
15.
Wariss
BR
,
de Souza Abrahão
K
,
de Aguiar
SS
,
Bergmann
A
,
Thuler
LCS
.
Effectiveness of four inflammatory markers in predicting prognosis in 2374 women with breast cancer
.
Maturitas
.
2017
;
101
:
51
6
.
16.
Xiang
Y
,
Zhang
N
,
Lei
H
,
Wu
J
,
Wang
W
,
Zhang
H
, et al
.
Neutrophil-to-lymphocyte ratio is a negative prognostic biomarker for luminal A breast cancer
.
Gland Surg
.
2023
;
12
(
3
):
415
25
.
17.
Kuang
T
,
Qiu
Z
,
Wang
K
,
Zhang
L
,
Dong
K
,
Wang
W
.
Panimmune inflammation value as a prognostic biomarker for cancer patients treated with immune checkpoint inhibitors
.
Front Immunol
.
2024
;
15
:
1326083
.
18.
Lin
F
,
Zhang
LP
,
Xie
SY
,
Huang
HY
,
Chen
XY
,
Jiang
TC
, et al
.
Pan-immune-inflammation value: a New prognostic index in operative breast cancer
.
Front Oncol
.
2022
;
13
:
830138
.
19.
Yamanouchi
K
,
Murakami
S
,
Sato
A
,
Ogawa
S
,
Shinagawa
H
,
Kamohara
Y
.
Integrated evaluation of inflammatory, nutritional, and sarcopenia markers to predict survival in metastatic breast cancer patients
.
In Vivo
.
2023
;
37
(
2
):
811
7
.
20.
Qi
X
,
Qiao
B
,
Song
T
,
Huang
D
,
Zhang
H
,
Liu
Y
, et al
.
Clinical utility of the pan-immune-inflammation value in breast cancer patients
.
Front Oncol
.
2023
;
13
:
13
:
1223786
.
You do not currently have access to this content.